scholarly journals Frontal fibrosing alopecia: An overview

2021 ◽  
Vol 0 ◽  
pp. 1-7
Author(s):  
Shaheela Backar
Keyword(s):  
Treatment Guidelines ◽  
Therapeutic Options ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Primary Progressive ◽  
Disease Characteristics

Frontal fibrosing alopecia (FFA) is a primary progressive cicatricial alopecia of the frontal, temporal, or frontotemporal scalp. In FFA, hairline recession, scalp pruritus, perifollicular erythema, and eyebrow loss are common at presentation. At present, there are no evidence-based treatment guidelines for FFA; hence, adopted modalities of treatment vary among clinicians. This review is an overview of the disease characteristics and the available therapeutic options in FFA.

Treatment of interictal psychiatric disorder in epilepsy. I. Affective and anxiety disorders

2002 ◽  
Vol 14 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Cm van der Feltz-Cornelis
Keyword(s):  
Anxiety Disorders ◽  
Psychiatric Disorder ◽  
Affective Disorders ◽  
Treatment Guidelines ◽  
Systematic Research ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
General Psychiatry ◽  
Dsm Iv ◽  
Patients With Epilepsy

Background:Interictal affective disorders are common in patients with epilepsy and there is a need for evidence-based treatment guidelines.Objective:This paper gives an overview of research concerning treatment of interictal affective disorders and interictal anxiety disorders in epilepsy.Methods:Literature review supplemented by clinical experience.Results:Interictal psychiatric disorder can be characterized as intermittent pleomorphic psychopathology. The most common manifestations are interictal dysphoric disorder (IDD) and depression. There is a lack of randomized control trials (RCTs) concerning effectiveness and side-effects of antidepressants in epilepsy patients.Conclusion:Treatment implications of the concept of IDD and other interictal disorders are an optimized dosage of anti-epileptics in combination with antidepressants. This coincides with recent guidelines concerning combinations of psychotropic medication, such as for depression and bipolar disorder, in general psychiatry. Systematic research involving the DSM-IV categories of generalized anxiety disorder, panic disorder and agoraphobia and depression is not yet available. Prevalence and treatment of interictal anxiety disorders and depressive disorder in epilepsy should be the subject of further research, in order to enable development of evidence-based treatment guidelines for these disorders in epilepsy patients.

PTSD Treatment of African American Adults in Primary Care: The Gap Between Current Practice and Evidence-Based Treatment Guidelines

2011 ◽  
Vol 103 (7) ◽  
pp. 585-593 ◽  
Author(s):  
Ruth Elaine Graves ◽  
John R. Freedy ◽  
Notalelomwan U. Aigbogun ◽  
William B. Lawson ◽  
Thomas A. Mellman ◽  
...  
Keyword(s):  
Primary Care ◽  
African American ◽  
Current Practice ◽  
Treatment Guidelines ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Ptsd Treatment ◽  
African American Adults

Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines

2005 ◽  
Vol 1 (3) ◽  
pp. 255-270 ◽  
Author(s):  
Frank Petrak ◽  
Stephan Herpertz ◽  
Christian Albus ◽  
Axel Hirsch ◽  
Bernhard Kulzer ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Psychosocial Factors ◽  
Treatment Guidelines ◽  
Evidence Based ◽  
Evidence Based Treatment

A practice transformation model to improve lung cancer care.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 92-92
Author(s):  
Daisy E. Escobar ◽  
Mohd Khushman ◽  
Jennifer Young Pierce ◽  
Cathy Tinnea ◽  
Austin Cadden ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Guidelines ◽  
Quality Care ◽  
Treatment Decision ◽  
Baseline Period ◽  
Transformation Model ◽  
Molecular Testing ◽  
Evidence Based ◽  
Exact Test ◽  
Evidence Based Treatment

92 Background: Lung cancer has the highest cause of cancer death, treatment of which is both complicated and expensive. Emerging actionable biomarkers and treatments provide both opportunity and treatment challenges. Adherence to evidence-based treatment and advanced care discussions add value to care. Oncology practices need to document the above to participate in value-based care reimbursement models. A Practice Transformation (PT) model was implemented to address quality and cost issues. Methods: After IRB approval, baseline data on lung cancer patients diagnosed during a 6-month period (Jul-Dec 2017) were collected through chart abstraction and treatment planning surveys. Rates of molecular testing ordered, results available at time of treatment decision-making, guideline concordant treatment decisions, and documentation of advanced care discussions were presented to the PT team. After education on recent clinical trial results and NCCN treatment guidelines, the PT team determined strategies for change. The PT team met after two 3-month periods of PT for education updates and progress reports. Data was compared on newly diagnosed patients during a 6-month period (Jul-Dec 2018), one year after the baseline period. Results: A total of forty-two patients were diagnosed in two 6-month periods, baseline and study period. Average age was 65 years, 57% male, 71% Caucasian, 95% ever smokers, 71% adenocarcinoma histology. Rate of ordering any molecular testing was (16/19) 84% in the baseline period vs (20/23) 86% in the study period. However, extended molecular testing increased from 16% (3/19) to 60% (12/20), p = .05 Fishers exact test. At treatment initiation, evidence-based treatment selections went from 47% to 52%. Documentation of advanced care discussions, 42% (8/19) to 56% (13/23), did not change significantly. Conclusions: A PT model that included education, and two cycles of implementation and feedback, resulted in increased molecular testing to inform evidence-based treatment selections. Increased awareness of the lack of documentation of advanced care discussions provides opportunity for continued improvement to effect quality care.

scholarly journals Lack of Adherence to Evidence-based Treatment Guidelines for Nontuberculous Mycobacterial Lung Disease

2014 ◽  
Vol 11 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Jennifer Adjemian ◽  
D. Rebecca Prevots ◽  
Jack Gallagher ◽  
Kylee Heap ◽  
Renu Gupta ◽  
...  
Keyword(s):  
Lung Disease ◽  
Treatment Guidelines ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Nontuberculous Mycobacterial Lung Disease

Established evidence‐based treatment guidelines help mitigate disparities in quality of emergency care

2021 ◽  
Author(s):  
Stacy A. Trent ◽  
Nigel George ◽  
Edward P. Havranek ◽  
Adit A. Ginde ◽  
Jason S. Haukoos
Keyword(s):  
Emergency Care ◽  
Treatment Guidelines ◽  
Evidence Based ◽  
Evidence Based Treatment

scholarly journals TRIMETHOPRIM-SULFAMETHOXAZOLE AND SODIUM VALPROATE-INDUCED TOXIC EPIDERMAL NECROLYSIS: A CASE SERIES

2021 ◽  
pp. 3-5
Author(s):  
BHAVANA SRIVASTAVA ◽  
RENU KHANCHANDANI ◽  
VIKRAM SINGH DHAPOLA ◽  
ZAFAR MASOOD ANSARI
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Sodium Valproate ◽  
Treatment Guidelines ◽  
Case Series ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Successful Recovery ◽  
Common Causes ◽  
Potential Risk Factors ◽  
Life Threatening

Toxic epidermal necrolysis (TEN) is a rare and serious but life-threatening dermolytic cutaneous reaction characterized by diffuse and severe exfoliation and destruction of the epidermis of skin and mucosa due to immunological damage of the epidermis which can bring about sepsis and respiratory distress. Drugs are the most common inflicting agents in the generation of TEN. Among drugs, antiepileptics, antipsychotics, and sulfa-drugs are common causes of TEN. Valproate is one of the most common drugs prescribed for epilepsy, was found as causative agent in TEN in very few cases. Among sulfonamides, sulfamethoxazole is commonly used antibiotic which can cause TEN. The evidence-based treatment guidelines are lacking, so the best approach is to recognize and evade potential risk factors and to deliver intensive supportive care immediately to reduce morbidity and mortality. The aim of this case series is to focus on valproate and trimethoprim-sulfamethoxazole (TMP-SMX)-induced TEN, which are commonly used drugs. Here, we present a case series of TEN inflicted by TMP-SMX and sodium valproate in a 23-year-old female and 10-year-old boy, respectively, with successful recovery.

Sign in / Sign up

Export Citation Format

Share Document